RxDoctor Payments DataLook up a doctor →

Santos Yu, MD

Neurology · Henderson, NVNPI 1861474181

Payments from drug & device makers

$22,686in general payments, 2019–2025

Across 1,281 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$1K
  • Novartis$1K
  • UCB, Inc.$1K
  • Lundbeck LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$1231%
  • Food & beverage$22,36699%
  • Education$1961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)293$4,186
Biogen91$1,483
Novartis135$1,461
UCB, Inc.53$1,087
Lundbeck LLC55$1,077
Teva Pharmaceuticals USA, Inc.64$1,044
Medtronic(2 entities)20$878
Abbott15$636
Pfizer31$604
Sanofi25$567
Neurocrine Biosciences, Inc.21$564
Amgen(2 entities)30$524
EMD Serono, Inc.31$520
Lilly USA, LLC31$446
AstraZeneca22$441
Genentech USA, Inc.20$432
Ipsen Biopharmaceuticals, Inc20$409
Argenx US, Inc.21$375
Acadia Pharmaceuticals Inc25$370
Otsuka America Pharmaceutical, Inc.13$320
Biohaven Pharmaceuticals, Inc.18$310
SK Life Science, Inc.14$293
MDD US Operations, LLC15$266
Avanir Pharmaceuticals, Inc.15$260
Merz North America, Inc.8$218
Biohaven Pharmaceutical Holding Company Ltd.11$205
Acorda Therapeutics, Inc13$188
Bristol Myers Squibb14$188
Johnson & Johnson(2 entities)9$181
Upsher-smith Laboratories LLC10$174
Merz Pharmaceuticals, LLC6$162
Adamas Pharmaceuticals, Inc.8$149
Jazz Pharmaceuticals Inc.6$128
E.r. Squibb & Sons, L.L.C.2$117
Catalyst Pharmaceuticals, Inc.5$114
Sanofi-aventis U.S. LLC6$112
Sunovion Pharmaceuticals Inc.6$104
Tanabe Pharma America, Inc.5$100
ANI Pharmaceuticals, Inc.4$99
Sumitomo Pharma America, Inc.4$96
Amneal Pharmaceuticals LLC6$96
Neuropace, Inc.3$94
Neurelis, Inc.5$90
Akcea Therapeutics, Inc.1$88
Vanda Pharmaceuticals Inc.3$86
Axsome Therapeutics, Inc.4$86
Corium, LLC3$78
Arbor Pharmaceuticals, Inc.5$74
Eisai Inc.3$74
Livanova USA, Inc.3$73
Inspire Medical Systems, Inc.1$61
Takeda Pharmaceuticals U.S.A., Inc.2$55
Saol Therapeutics Inc.3$52
Mallinckrodt Hospital Products Inc.3$51
Harmony Biosciences LLC2$46
Scilex Pharmaceuticals Inc.3$46
Grifols USA, LLC2$44
Assertio Therapeutics, Inc.3$44
GE HealthCare2$43
Tersera Therapeutics LLC2$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,686 in reported general payments places this provider in the 75th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$381,367
Medicare patients
1,187
Services billed
3,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5022$269,041
PanzygaImmun Glob G(Igg)-Ifas/Glycine13$233,162
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$216,457
Avonex (4 Pack)Interferon Beta-1a13$107,138
GammakedImmune Globul G/Gly/Iga Avg 4611$84,507
OctagamImmun Globg(Igg)/Malt/Iga Ov5018$79,797
BotoxOnabotulinumtoxina65$73,733
GlatopaGlatiramer Acetate22$42,759
Dalfampridine ErDalfampridine21$13,798
QuliptaAtogepant11$11,620
Dimethyl Fumarate43$7,007
Memantine Hcl380$6,094
Pregabalin264$5,286
Gabapentin370$3,717
Pyridostigmine Bromide52$3,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Octagam$604$312,95931 claims
BiogenAvonex (4 Pack)$1,483$107,13813 claims
AbbVieBotox, Qulipta$4,186$85,35276 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$96$4,49869 claims
Upsher-smith Laboratories LLCTopiramate$174$1,549178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 145 neurology providers in Nevada.

Other neurology in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →